Accessibility Menu
Alliance Pharma Plc logo

Alliance Pharma Plc(LSE) APH

This security has been delisted. This page is retained for historical reference.

Alliance Pharma Plc last closing stock price
MetricPriceDate
Last closeGBX 64.702025-05-14
Alliance Pharma Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.15%GBX 64.602025-05-07
1 month+0.78%GBX 64.202025-04-14
3 month+5.2%GBX 61.502025-02-13
Year to date+41.42%GBX 45.752024-12-31
1 year+88.63%GBX 34.302024-05-14
3 year-41.71%GBX 111.002022-05-13
5 year-11.37%GBX 73.002020-05-15
Since inception+332.58%GBX 0.152003-12-23

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

APH Financials

Key Financial Metrics (TTM)

Gross Margin

61.11%

Operating Margin

-4.53%

Net Income Margin

-6.00%

Return on Equity

-5.04%

Return on Capital

-2.67%

Return on Assets

-2.91%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

£194.28M

Operating Income

£69.23M

EBITDA

-£24.02M

Operating Cash Flow

£51.96M

Capital Expenditure

-£1.54M

Free Cash Flow

£50.42M

Cash & ST Invst.

£32.36M

Total Debt

£95.70M

Alliance Pharma Plc Performance Analysis

Alliance Pharma Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31GBP 163,207,000N/A
20222022-12-31GBP 167,416,0002.6%
20232023-12-31GBP 180,680,0007.9%
20242024-12-31GBP 178,836,000-1.0%
Alliance Pharma Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30-8.2%
Q42023-12-3122.0%
Q22024-06-30-15.5%
Q42024-12-3113.2%
Alliance Pharma Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31GBP 0.01N/A
20222022-12-31GBP -0.04N/A
20232023-12-31GBP -0.0656.2%
20242024-12-31GBP -0.02-67.8%
Alliance Pharma Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30141.8%
Q42023-12-31-853.2%
Q22024-06-30112.1%
Q42024-12-31-431.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

£94.97M

+7.1%

Gross Profit

£53.77M

+17.9%

Gross Margin

56.61%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

290

N/A

Net Income

-£15.39M

-26.5%

EBITDA

-£11.26M

-362.1%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

£32.36M

+2.0%

Total Debt

£95.70M

-28.4%

Accounts Receivable

£46.34M

-3.9%

Inventory

£22.52M

-7.3%

Long Term Debt

£95.10M

-30.6%

Short Term Debt

£596.00K

-2.8%

Return on Assets

-2.91%

N/A

Return on Invested Capital

-2.44%

N/A

Free Cash Flow

£20.35M

+94.4%

Operating Cash Flow

£20.47M

+94.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BMK.LBenchmark Holdings plc
£0.22+4.01%
MGP.LMedica Group Plc
£2.12+0.47%
INS.LInstem plc
£8.29-0.12%
MXCT.LMaxCyte, Inc.
£1.48-7.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.